A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome
Enrollment status: Open
In this study, patidegib topical gel is being evaluated as a topical (applied to skin) treatment for BCNS. The main purpose of this study is to see if the study gel, which is applied to the face, reduces the number of new surgically eligible BCCs and learn more about the safety of the study gel. This information will be obtained by taking samples of your blood and urine, collection of medical exams performed by the study doctor, collection of images of your facial area, and by taking biopsies (tissue samples) of your skin.
Study coordinator: Aaron Rankin, (734) 936-7519 or email@example.com
Please reference Derm #: 729